Entera Bio (ENTX)
(Delayed Data from NSDQ)
$2.51 USD
+0.17 (7.26%)
Updated May 14, 2024 04:00 PM ET
After-Market: $2.43 -0.08 (-3.19%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Entera Bio Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 9 | 13 | 12 | 11 | 11 |
Income After Depreciation & Amortization | -9 | -13 | -12 | -11 | -11 |
Non-Operating Income | 0 | 0 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -9 | -13 | -12 | -10 | -11 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -9 | -13 | -12 | -10 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -9 | -13 | -12 | -10 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -13 | -12 | -11 | -11 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -9 | -13 | -12 | -11 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.01 | 28.81 | 26.13 | 18.56 | 12.15 |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.45 | -0.47 | -0.55 | -0.89 |
Diluted Net EPS (GAAP) | -0.31 | -0.45 | -0.47 | -0.55 | -0.89 |
Fiscal Year end for Entera Bio Ltd falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.96 | 2.39 | 2.33 | 2.21 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.96 | -2.39 | -2.33 | -2.21 |
Non-Operating Income | NA | -0.03 | 0.04 | 0.01 | 0.02 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.99 | -2.35 | -2.33 | -2.19 |
Income Taxes | NA | 0.00 | 0.03 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.02 | -2.00 | -2.38 | -2.33 | -2.19 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.02 | -2.00 | -2.38 | -2.33 | -2.19 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 36.74 | 28.50 | 28.81 | 28.81 | 28.81 |
Diluted EPS Before Non-Recurring Items | -0.05 | -0.07 | -0.08 | -0.08 | -0.08 |
Diluted Net EPS (GAAP) | -0.05 | -0.07 | -0.08 | -0.08 | -0.08 |